Quantinno Capital Management LP Increases Stake in Repligen Co. (NASDAQ:RGEN)

Quantinno Capital Management LP raised its stake in shares of Repligen Co. (NASDAQ:RGEN) by 10.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,957 shares of the biotechnology company’s stock after purchasing an additional 193 shares during the period. Quantinno Capital Management LP’s holdings in Repligen were worth $291,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of RGEN. Toronto Dominion Bank increased its holdings in shares of Repligen by 1.5% during the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after buying an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale increased its stake in Repligen by 1.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after acquiring an additional 89 shares during the last quarter. Ballentine Partners LLC increased its stake in Repligen by 6.2% during the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock worth $269,000 after acquiring an additional 105 shares during the last quarter. CWM LLC lifted its stake in shares of Repligen by 36.3% in the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 114 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Repligen by 24.0% during the 3rd quarter. GAMMA Investing LLC now owns 594 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 115 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

RGEN has been the topic of several research reports. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, November 22nd. Wells Fargo & Company initiated coverage on shares of Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Finally, Wolfe Research started coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Stock Up 0.3 %

RGEN stock opened at $156.41 on Monday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a 50 day simple moving average of $142.66 and a 200-day simple moving average of $141.59. The company has a market capitalization of $8.76 billion, a P/E ratio of -422.73, a PEG ratio of 4.64 and a beta of 0.96. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.23 EPS. On average, equities research analysts predict that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.